La vendita allo scoperto per United States Cellular Corporation 5.500% Senior Notes due 2070 dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di United States Cellular Corporation 5.500% Senior Notes due 2070. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

United States Cellular Corporation 5.500% Senior Notes due 2070 (NYSE:UZE) Azioni, Report sulle vendite allo scoperto

United States Cellular Corporation 5.500% Senior Notes due 2070

Wells Fargo analyst Michael Turrin maintains Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) with a Overweight and lowers the price target from $350 to $345.

News

Price Target

Analyst Ratings

ADSK

Wells Fargo Maintains Overweight on Autodesk, Lowers Price Target to $345

Earnings

Earnings Misses

BCBP

BCB Bancorp Q1 2025 GAAP EPS $(0.51)

<a href="https://www.globenewswire.com/Tracker?data=o7V-0SsTOHcenMZhmD2dP3UDv-B6ZjmQQRaqf3TU9Xxc2D4W30ZgtSDO8Nzo8n8svBJUXmyQNpOH8OBE5UkRKUXO9jX6T6JGp6jXKDd4FsA=">Banzai International, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNZI#NASDAQ">BNZI</a>) ("Banzai" or the "Company"), a leading marketing technology company that provides essential marketing and sales solutions, today announced that it has issued 1,048,920 shares of common stock to Alco Investment Company ("Alco"), pursuant to an exercise notice for Pre-Funded Warrants received on September 20, 2024 for a purchase price of $3.89.
On September 20, 2024, the Company completed a private placement of securities pursuant to which Alco acquired 282,420 shares of Class A Common Stock for a purchase price of $3.89 per share, Pre-Funded Warrants to purchase up to 1,048,920 shares of Class A Common Stock with an exercise price of $0.0001 per share for a purchase price of $3.89 per Pre-Funded Warrant, and Common Warrants to purchase up to 1,331,340 shares of Class A Common Stock with an exercise price of $4.02 per share. Alco has not sold any shares issued under the private placement.
All Pre-Funded Warrants were net exercised on a cashless basis, resulting in a total number of Class A common shares outstanding of 14,470,727 as of April 21, 2025. Following the exercise, Alco will own 9.5% of the Company's Class A Common Stock.

Offerings

BNZI

Banzai Issues 1,048,920 Shares To Alco Investment Company, Bringing Alco's Ownership To 9.5% Of Outstanding Class A Common Stock As Total Shares Rise To 14.47M

Wells Fargo analyst Michael Turrin maintains Adobe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) with a Overweight and lowers the price target from $600 to $430.

ADBE

Wells Fargo Maintains Overweight on Adobe, Lowers Price Target to $430

Baird analyst Joe Vruwink maintains PTC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) with a Outperform and raises the price target from $181 to $185.

Baird Maintains Outperform on PTC, Raises Price Target to $185

Baird analyst Catherine Ramsey maintains Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) with a Outperform and lowers the price target from $407 to $355.

Baird Maintains Outperform on Waters, Lowers Price Target to $355

Wells Fargo analyst Michael Turrin maintains 8x8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGHT#NASDAQ">EGHT</a>) with a Underweight and lowers the price target from $2 to $1.5.

EGHT

Wells Fargo Maintains Underweight on 8x8, Lowers Price Target to $1.5

Partnership to Feature Autonomous Drive-Thru with AI Technology and In-Suite Premium Coffee Integration
BREA, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Reborn Coffee Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REBN#NASDAQ">REBN</a>), a leader in the specialty coffee market, today announced that it has entered into a Memorandum of Understanding ("MOU") with Otonomus Hotel, marking a groundbreaking collaboration to reimagine the future of hospitality and retail coffee service.
The strategic partnership will bring together Reborn Coffee's specialty coffee expertise with Otonomus Hotel's pioneering AI-powered hospitality vision. At the heart of the collaboration is the co-development of a next-generation autonomous drive-thru coffee experience utilizing cutting-edge AI technology — an advanced, fully autonomous ordering and fulfillment system. The AI-enabled Reborn drive-thru will be prominently located at the front of the Otonomus Hotel, accessible to both hotel guests and the public.
In addition, the partnership will extend into every guest room with premium in-suite Reborn offerings, including cold brew cans, single-serve coffee capsules, and smart coffee machines. Select suites may also feature curated Reborn welcome kits for a personalized touch.
The MOU will remain in effect for an initial term of six months as both parties finalize operational and revenue-sharing details. The agreement is non-binding and subject to further definitive documentation.
 &nbsp;

REBN

Reborn Coffee Enters Into MoU With Otonomus Hotel To Launch AI-driven Hospitality Experience

Wells Fargo analyst Michael Berg maintains Sprinklr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXM#NYSE">CXM</a>) with a Underweight and lowers the price target from $7 to $6.

Wells Fargo Maintains Underweight on Sprinklr, Lowers Price Target to $6

A Dose-Dependent Response in Body Weight Reduction Was Observed Between 8 mg and 32 mg Doses
Change in BMI and Body Weight Adjusted for Height In the Treatment Groups, Showed a Significant Difference Compared to Placebo, Indicating Potentially Greater Efficacy with Increasing Dosage and Longer Duration of Use
No Drug-Induced Cardiovascular Effects Were Observed In Heart Rate or QTcF Measurements of Subjects Receiving up to 32 mg of DA-1726 at 4-Weeks
Additional Cohorts Being Added to Determine Maximum Tolerated Dose
CAMBRIDGE, Mass., April 22, 2025 /PRNewswire/ -- MetaVia Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTVA#NASDAQ">MTVA</a>),&nbsp;a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today reported additional top-line results from the multiple ascending dose (MAD) Part 2 of its Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), further demonstrating its potential as a best-in-class obesity drug.
In the 28-day, 36-subject MAD portion of the study, a clear dose-responsive trend in body weight (BW) reduction was observed across the 8 mg to 32 mg range, indicating potentially greater efficacy at higher doses and longer duration of use. Additionally, body mass index (BMI), which shows body weight adjusted for height, showed a difference between the treatment group and the placebo (PBO) group, which was even more pronounced, further supporting the dose-dependent effect of the drug on weight-related outcomes. Of note, DA-1726 did not show any clinically significant increases in heart rate (HR) or QTcF changes up to 32 mg at 4 weeks of administration.
As previously reported, with no titration, DA-1726, with its novel 3:1 ratio between GLP-1R and GCGR at the 32 mg dose, demonstrated&nbsp;compelling maximum weight&nbsp;loss of -6.3% and mean weight loss of -4.3% at Day 26 (p=0.0005), while showing a strong signal of GLP-1R efficacy with maximum lowering of fasted glucose of -18 mg/dL&nbsp;and mean lowering of -5.3 mg/dL&nbsp;at Day 26,&nbsp;and maximum waist circumference reduction of 3.9 inches and mean reduction of 1.6 inches, indicating a strong signal of glucagon efficacy at Day 33.

Biotech

General

MTVA

MetaVia Reports Additional Top-Line Results From The MAD Part 2 Of Its Phase 1 Study Of DA-1726, A Novel 3:1 Ratio GLP-1 And Glucagon Dual Receptor Agonist To Treat Obesity; No Drug-Induced Cardiovascular Effects Were Observed In Heart Rate Or QTcF Measurements Of Subjects Receiving Up To 32mg Of DA-1726 At 4-Weeks; Additional Cohorts Being Added to Determine Maximum Tolerated Dose

Zions Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZION#NASDAQ">ZION</a>) posted weaker-than-expected results for the <a href="https://www.benzinga.com/quote/ZION/earnings">first quarter on Monday</a>.
The company reported first-quarter revenue of $795 million, missing analyst estimates of $797.07 million, according to Benzinga Pro. The bank reported first-quarter earnings of $1.13 per share, missing analyst estimates of $1.17 per share.
"Credit quality remained in very good shape during the quarter, with nonperforming assets stable compared with last quarter at 0.51% of loans and leases and annualized net charge-offs of 0.11% of loans and leases. At the same time, the outlook for the economy is perhaps more uncertain than it's been in a number of years, clouded by the very real potential for negative impacts from tariffs and trade policy, both here and abroad," said Harris Simmons, chairman and CEO of Zions Bancorp.
Zions Bancorp shares dipped 1.5% to close at $43.62 on Monday.
These analysts made changes to their price targets on Zions Bancorp following earnings announcement.
<ul>
<li>Stephens &amp; Co. analyst Terry McEvoy maintained Zions Bancorp with an Equal-Weight rating and lowered the price target from $54 to $52.</li>
<li>Baird analyst David George maintained the stock with a Neutral rating and lowered the price target from $58 to $55.</li>
<li>Wells Fargo analyst Mike Mayo maintained Zions Bancorp with an Equal-Weight rating and cut the price target from $58 to $47.</li>
</ul>
Considering buying ZION stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="597" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22083157/image-1-20-1024x597.png" alt="" class="wp-image-881789" style="width:662px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22083157/image-1-20-1024x597.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22083157/image-1-20-300x175.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22083157/image-1-20-768x448.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22083157/image-1-20.png 1106w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44896269/how-to-earn-500-a-month-from-3m-stock-ahead-of-q1-earnings">How To Earn $500 A Month From 3M Stock Ahead Of Q1 Earnings</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

Trading Ideas

ZION

These Analysts Lower Their Forecasts On Zions Bancorp After Downbeat Earnings

<a href="https://www.globenewswire.com/Tracker?data=6ooRSXKOQZ4CJWJdD6Tsqq4LjLykPLUcHYMMpFfgG7N9fD-Zh5bL3vAPFwP-UQSX7T9H9tOny3XPrYdw5eSlo6dqLr4RoB2bvYTBnVSdtNgyL4L-7zqefQl_gijny0u0">KULR Technology Group, Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KULR#NYSE">KULR</a>) (the "Company" or "KULR"), a leader in advanced energy management platforms, announced today that it has been awarded $6,703,500 by the Texas Space Commission as part of a $26 million grant award focused on strengthening Texas' leadership in space exploration and technology. The announcement was made public by the Commission and covered by <a href="https://www.globenewswire.com/Tracker?data=8XCuYTS-kdBRiisJoZgTsNEJNsEdiaXr0pQBlCaMbn7TIHjv-aydaFDjdel6LhGS5P2ba4KPdvKDaFlEcZn1zty8grgAIFOwvx87BaJIFBlLO-fdfLCLKaxyQUQZqQxoAFxCz1v0NByQysieFteHXBB1jTzn5KTzvcPRLRRNJYA=">SpaceNews</a>.
KULR's selection supports its role in an ambitious program to develop cold-temperature lithium-ion battery solutions for the next generation of Lunar and Martian missions. The initiative is being carried out in close collaboration with <a href="https://www.globenewswire.com/Tracker?data=oMgvYznLtJqnX0zwVdVBYfucZWDeJzpnwj4Ui_XbKEx6kLNuQ-LWkOPRCX9hCEKRXkEHSEVUL04NizyXZ3q-DXoVQyJK8AScOllaFiYtyp9X2QfM8flnXGMvxQFPRPgE">NASA Johnson Space Center</a> (JSC) and in partnership with <a href="https://www.globenewswire.com/Tracker?data=ENC6hdmbd5YUHK7ytodbLzoWWmu8D3TF1PyCRB_gwAjb2kl6hK6YPvTD6-ClvEwqzp5LgitktcpI2NWfK-srquKDI1cmkwWXPPwWDda2Vco=">South 8 Technologies</a>, aligning public, private, and academic stakeholders to deliver scalable, space-rated battery technology.
"This award underscores KULR's commitment to powering the next era of space exploration with safe, high-performance, and environmentally adaptive KULR ONE Space platform," said Michael Mo, CEO of KULR Technology Group. "Working alongside visionary partners at NASA JSC and South 8, we're proud to anchor this Texas-led effort to develop scalable, space-rated battery technology that advances national objectives and commercial innovation."
Throughout the program, KULR will manage the design, testing, and production of lithium-ion cells using liquefied gas (LiGas) electrolyte from South 8 Technologies. These cells will operate down to -60°C and be integrated into the KULR ONE Space platform, optimized for extreme environments encountered during lunar and Martian missions.
Located just minutes from NASA Johnson Space Center, KULR's Webster, TX facility will serve as the engineering and test hub for this effort, performing advanced battery safety testing and performance validation. The project aligns with NASA's Artemis objectives by reducing heater energy requirements, improving safety margins, and enabling longer-duration operations in deep space environments.

Financing

KULR

Kulr Technology Awarded Over $6.7M By Texas Space Commission As Part Of $26M Grant Award Focused On Strengthening Texas' Leadership In Space Exploration And Technology

President Donald Trump held a meeting with the CEOs of Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>), Home Depot Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>), and Target Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) on Monday.
What Happened: The meeting was centered around the possible effects of Trump&#8217;s wide-ranging tariff plans on the import-centric business models of these retail behemoths. Walmart&#8217;s CEO Doug McMillon, Target CEO Brian Cornell, and Home Depot&#8217;s Ted Decker attended the meeting, <a href="https://www.cnbc.com/2025/04/21/trump-tariffs-walmart-home-depot-lowes-target.html">CNBC </a>reported.
Despite initial reports of a representative from&nbsp;Lowe&#8217;s Companies Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) attending, it was later confirmed that Lowe&#8217;s was not represented at the meeting.
Post-meeting, the three companies issued similar statements, expressing gratitude for the opportunity to share their insights with the President and his team. They pledged their commitment&nbsp;to delivering value for American&nbsp;consumers and expressed eagerness to continue the dialogue. 
President Trump later expressed satisfaction with the meeting, stating it was an honor to host the retail leaders in the Oval Office.
David French, the executive vice president for government relations at the National Retail Federation, previously told the New York Times, "The deal window may be open.&#8221;
SEE ALSO:&nbsp;<a href="https://benzinga.com/markets/25/04/44916042/general-motors-has-no-plans-to-move-ev-production-away-from-mexico-despite-tariff-uncertainty" target="_blank" rel="noreferrer noopener">General Motors Has No Plans To Move EV Production Away From Mexico Despite Tariff Uncertainty</a>
Why It Matters: Walmart sources about one-third of its products globally, with China and Mexico being the most significant suppliers. Meanwhile, Target, known for affordable fashion and home goods, primarily relies on overseas manufacturing for these items. For these retailers, tariffs present a new hurdle in an already challenging economic environment, where consumers are seeking low prices amidst high inflation.
Leading industry lobbying groups from agriculture, construction, manufacturing, retail, and tech are urging the White House to ease more tariffs, arguing that certain products are too costly or impractical to produce domestically and must be imported. Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) CEO Tim Cook reportedly <a href="https://www.benzinga.com/25/04/44882019/apple-ceo-tim-cooks-dialogue-with-commerce-secretary-lutnick-secured-tariff-exemption-for-iphones-and-electronics-report">negotiated </a>with the White House and obtained relief for both his company and the wider electronics industry. Trump also later stated that he &#8216;helped&#8217; the CEO and his business. 
Nevertheless, earlier this month,&nbsp;<a href="https://www.benzinga.com/news/guidance/25/04/44711688/walmart-maintains-steady-growth-forecast-despite-tariffs">Walmart</a>&nbsp;reaffirmed its first-quarter guidance, indicating steady sales growth despite the looming tariffs. The retail giant continues to project a sales growth of 3% – 4% in constant currencies for the first quarter of FY26.
Meanwhile, a recent&nbsp;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44797563/goldman-sachs-sees-upside-in-retail-giants-dollar-tree-home-depot-best-buy-and-target-despite-tariff-margin-pressures">Goldman Sachs analysis</a>&nbsp;highlighted the potential impact of China tariffs on profitability for Home Depot and Target. The report suggests that despite tariff and margin pressures, there might be an upside for these retail giants.
Benzinga's Edge Rankings&nbsp;highlight strong momentum and growth rankings for Walmart in the 94th and 55th percentiles, respectively. Curious how other stocks stack up?&nbsp;<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound" target="_blank" rel="noreferrer noopener">Click here</a>&nbsp;to uncover growth and momentum scores for top stocks.
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/markets/cryptocurrency/25/04/44917155/xrp-leads-ethereum-bleeds-as-crypto-investment-products-see-6-million-in-inflows" target="_blank" rel="noreferrer noopener">XRP Leads, Ethereum Bleeds As Crypto Investment Products See $6 Million In Inflows &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

Economics

AAPL

Trump Meets With Walmart, Home Depot And Target CEOs To Discuss Tariff Impacting Consumer Prices

Pioneer in Video Surveillance Technology Marks 16 Years of DHS Recognition with Advanced AI Designation
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.iveda.com&amp;esheet=54241135&amp;newsitemid=20250422024839&amp;lan=en-US&amp;anchor=Iveda%26%23174%3B&amp;index=1&amp;md5=1fced85515a52c6468803bf3a4b60a38">Iveda&#xAE;</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVDA#NASDAQ">IVDA</a>)––the global leader in AI-driven video analytics and IoT-based intelligent solutions, today announced that it has been awarded the Developmental Testing and Evaluation (DT&amp;E) designation under the Department of Homeland Security's SAFETY Act (Support Anti-terrorism by Fostering Effective Technologies Act of 2002). This significant milestone reinforces Iveda's long-standing relationship with DHS, which began in 2009, and underscores the company's decades-long commitment to developing advanced security technologies and AI-powered surveillance solutions that meet rigorous government standards.
The DT&amp;E designation, confirmed on February 28, 2025, recognizes IvedaAI as a technology with substantial potential for homeland security applications. This designation provides important liability protections while demonstrating the robust capabilities of Iveda's solutions in addressing critical security challenges.

IVDA

Iveda Awarded Developmental Testing And Evaluation Designation Under Department Of Homeland Security's SAFETY Act

Wells Fargo analyst Michael Berg maintains Monday.Com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) with a Overweight and lowers the price target from $380 to $310.

MNDY

Wells Fargo Maintains Overweight on Monday.Com, Lowers Price Target to $310

Tarsus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TARS#NASDAQ">TARS</a>) will present four distinct data sets highlighting the global prevalence and real-world patient burden of Demodex blepharitis, as well as the impact of XDEMVY&#xAE; (lotilaner ophthalmic solution) 0.25% in addressing objective measures of disease at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting, taking place April 25-28, 2025, in Los Angeles, Calif.

TARS

Tarsus To Present Several Scientific Abstracts Highlighting The Global Prevalence Of Demodex Blepharitis And The Clinical Impact Of XDEMVY At The ASCRS 2025 Annual Meeting

Wells Fargo analyst Michael Berg maintains Klaviyo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVYO#NYSE">KVYO</a>) with a Equal-Weight and lowers the price target from $45 to $26.

KVYO

Wells Fargo Maintains Equal-Weight on Klaviyo, Lowers Price Target to $26

Company expands Intelligent Fingerprinting Drug Screening System multilingual capabilities to meet growing demand across Latin American Spanish-speaking markets
Latin American drug screening market projected to reach USD 1.1 billion by 2030
Expansion is part of major multilingual Drug Screening System upgrade, targeting over 4 billion potential users worldwide
NEW YORK, April 22, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INBS#NASDAQ">INBS</a>) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the integration of Latin American Spanish into its Intelligent Fingerprinting Drug Screening System (the "System"). The enhancement allows users to operate the System in English, Arabic, and Latin American Spanish, extending the platform's usability across diverse, international settings.

Intelligent Bio Solutions Inc. - Common Stock

INBS

Intelligent Bio Solutions Integrates Latin American Spanish Into Intelligent Fingerprinting Drug Screening System

TOYO

TOYO Begins Production In 2GW Solar Cell Facility

WIIM

TIVC

Tivic Health shares are trading higher after the company said it held briefings with the White House and FDA, which garnered interest in potential military and defense applications for its product candidates.

Comments

United States Cellular Corporation 5.500% Senior Notes due 2070

Vendite allo scoperto

United States Cellular Corporation 5.500% Senior Notes due 2070 (NYSE:UZE) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO